Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Increasing pannexin 1 levels might be a novel treatment for rhabdomyosarcoma

Xiang X et al. Oncogenesis; 21 Nov. 2018. https://doi.org/10.1038/s41389-018-0100-4

Key clinical point: Pannexin 1 alleviated rhabdomyosarcoma malignant properties in vitro and in a mouse model through a process that is independent of its canonical channel function. Increasing pannexin 1 levels might be a novel therapeutic approach for rhabdomyosarcoma.

Main finding: Pannexin 1 transcript and protein levels in rhabdomyosarcoma cells were comparable to those seen in proliferative and undifferentiated skeletal muscle myoblasts, but pannexin 1 expression was down-regulated in embryonal and alveolar rhabdomyosarcoma samples, suggesting that the down-regulation may be involved in the malignant phenotype of rhabdomyosarcoma. Ectopic expression of pannexin 1 significantly reduced rhabdomyosarcoma malignant properties in vitro and in a mouse model. The effect was seen in embryonal and alveolar rhabdomyosarcomas even though their background of genetic alterations differs.

Study details: Pannexin 1 levels were measured using immunolabeling in 13 pediatric rhabdomyosarcoma tumor, 7 embryonal rhabdomyosarcomas and 6 alveolar rhabdomyosarcomas, as well as in 7 skeletal muscle samples from healthy children.

Disclosures: The authors declared having no relevant disclosures.

Source: Xiang X et al. Oncogenesis; 21 Nov. 2018. https://doi.org/10.1038/s41389-018-0100-4

Citation:

Xiang X et al. Oncogenesis; 21 Nov. 2018. https://doi.org/10.1038/s41389-018-0100-4